Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

McKesson (MCK) delivered earnings and revenue surprises of 0.00% and 4.88%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) Q2 Earnings Meet Estimates

McKesson Corp. MCK, +2.69% reported Wednesday a fiscal second-quarter profit that matched expectations while revenue rose well above expectations, amid strength in its U.S.

McKesson matches profit expectations, but sales rise well above forecasts

McKesson's (MCK) Pharmaceutical and Specialty Solutions unit is expected to have driven its fiscal Q2 results.

McKesson (MCK) to Report Q2 Earnings: What's in the Offing?

Boeing

Altria

Exxon Mobil

With the S&P 500 up almost 20% this year and the third-quarter earnings coming in pretty much as expected, it has been another solid year for stock investors.

4 Fallen Angel Large-Cap Blue Chips May Have Massive 2020 Rebounds

AmerisourceBergen

Cardinal Health

Teva Pharmaceutical

The first federal trial on the opioid crisis in the United States has been scrapped, after the court agreed to a $260m (£200m) settlement by the country's three largest drug distributors.

US drug giants settle first federal opioids lawsuit for $260m

Four drug companies plan to announce settlements Monday ahead of a massive trial that would accuse them of helping to fuel the nation's crippling opioid crisis, according to a report.

Drug Firms Reportedly Ink Last-Minute Deal Ahead Of Ohio Opioid Trial

CLEVELAND – Four drug companies reached a last-minute legal settlement over their role in the opioid addiction epidemic just as a nine-week trial was scheduled to start in Cleveland, the Wall Street Journal reported Monday.

Four drug companies reach legal settlement for role in opioid addiction epidemic

But drug companies still have thousands of other opioid cases to contend with.

$260 Million Settlement Averts First Federal Opioid Trial

Four drug companies reached a last-minute legal settlement over their role in the opioid addiction epidemic just as a nine-week trial was scheduled to start in Cleveland, the Wall Street Journal reported Monday.

Drug companies reach settlement as opioid trial set to begin

Four drug companies on Monday reached a settlement deal with two Ohio counties on the fight over who is responsible for the opioid epidemic that has ravaged the United States, according to a report in The Wall Street Journal.

Four drug companies reportedly reach a last-minute opioid settlement with two Ohio counties

Shares of McKesson Corp. MCK, +1.16% , Cardinal Health Inc. CAH, +0.64% , AmerisourceBergen Corp.

McKesson, Cardinal Health, Amerisource Bergen and Teva stocks all fall after settling with Ohio counties on opioid suit

Johnson & Johnson

The biggest drug distributors, plus Johnson & Johnson and Teva Pharmaceutical, are reportedly on the brink of a $50 billion deal to settle thousands of cases related to the opioid epidemic.

Drug Suppliers Reportedly Near $50 Billion Deal In Opioid Lawsuits

Talks to settle opioid lawsuits sent drug distributor stocks soaring. Trade names at the center of the discussions using these strategies.

Drug Distributor Stocks Rally Amid Opioid Talks

Shares of companies embroiled in the U.S. opioid crisis were trading sharply higher Wednesday following a Tuesday Wall Street Journal report that said three opioid drug distributors are in talks with state and local governments regarding a settlement agreement.

Opioid Drug Companies Rally On Hopes of Broader Settlement

Shares of McKesson Corp. MCK, +6.21% rallied 5.7% in midday trading Wednesday, enough to pace all of its larger-capitalization health care peers, after The Wall Street Journal reported that the drug distributor, and two others, were in talks to pay $18 billion to settle all litigation brought by state and local governments blaming the companies for fueling the opioid crisis.

McKesson, Cardinal Health, AmerisourceBergen stocks surge after WSJ report of $18 billion settlement talks

CVS Health

Walmart

Increasing lawsuits against pharmaceutical companies are likely to impact retailers and distributors.

Opioid Overdose Crisis in US Likely to Affect These 3 Stocks

D.R. Horton

AT&T

AT&T, McKesson and D.R. Horton still may offer upside in a pricey market.

3 Bargain Blue Chips With Momentum As Stocks Near Peak

McKesson (MCK) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.

Looking for Value? Why It Might Be Time to Try McKesson (MCK)

McKesson's stock is up nearly 25% this year, the first sign of relief for shareholders in several years.

McKesson Could Surge On A Settlement

Seagate Technology Holdings PLC

O'Reilly Automotive

The stock charts of STX, ORLY and MCK are headed into the middle of the week on the verge of significant moves.
The post 3 Big Stock Charts for Wednesday: McKesson, O’Reilly Automotive and Seagate Technology appeared first on InvestorPlace.

3 Big Stock Charts for Wednesday: McKesson, O’Reilly Automotive and Seagate Technology

McKesson Corporation (MCK) CEO Brian Tyler on Q1 2020 Results - Earnings Call Transcript

McKesson (MCK) delivered earnings and revenue surprises of 8.88% and 3.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) Q1 Earnings and Revenues Top Estimates

The drug distributor got off to a great start in its new fiscal year.

Good Times Are Here Again for McKesson

Shares of McKesson Corp. MCK, -2.50% rose more than 3% in the extended session Wednesday after the health-care company reported fiscal 2020 first-quarter per-share profit below Wall Street expectations but raised its profit guidance for the year and its quarterly dividend.

McKesson stock higher after company ups guidance, dividend

On Wednesday, July 31, McKesson (NYSE: MCK) will release its latest earnings report.

News for McKesson Stock (MCK)